The tumour suppressor genes, TP53 and RB1, and four genes involved in their regulation, INK4a, ARF, MDM2 and MDMX, were analysed in a series of 36 postradiotherapy radiation-induced sarcomas. One-third of the tumours developed in patients carrying a germline mutation of RB1 that predisposed them to retinoblastoma and radiation-induced sarcomas. The genetic inactivation of RB1 and/or TP53 genes was frequently observed in these sarcomas. These inactivations were owing to an interplay between point mutations and losses of large chromosome segments. Radiation-induced somatic mutations were observed in TP53, but not in RB1 or in the four other genes, indicating an early role of TP53 in the radio-sarcomagenesis. RB1 and TP53 genes were biallelically coinactivated in all sarcomas developing in the context of the predisposition, indicating that both genes played a major role in the formation of these sarcomas. In the absence of predisposition, TP53 was biallelically inactivated in one-third of the sarcomas, whereas at least one allele of RB1 was wild type. In both genetic contexts, the TP53 pathway was inactivated by genetic lesions and not by the activation of the ARF/MDM2/MDMX pathway, as recently shown in retinoblastomas. Together, these findings highlight the intricate tissue-and aetiologyspecific relationships between TP53 and RB1 pathways in tumorigenesis.
Introduction
It is now well established that cancer can occur after exposure to ionizing radiation from accidental, occupational or medical sources (Moysich et al., 2002; Wakeford, 2004) . Radiation-induced tumours are rare in adults (Travis, 2002) , but are among the most frequent secondary cancers for patients treated by radiotherapy for a first cancer during childhood (Menu-Branthomme et al., 2004) . The risk of radiation-induced tumour is especially elevated for patients with some germline mutations predisposing to sporadic cancers. Most of the reported cases occur in patients predisposed to bilateral retinoblastoma, a rare childhood cancer, linked to the germline inactivation of one allele of the tumour suppressor gene RB1. In this genetic background, the cumulative incidence of secondary tumours, mainly sarcomas, after radiotherapy may reach 38%, 50 years after diagnosis, whereas it does not exceed 21% in the absence of radiotherapy (Aerts et al., 2004; Kleinerman et al., 2005) . We recently analysed the presence of TP53 mutations in a series of sarcomas developing in the irradiation field in patients treated by radiotherapy. One-third of these patients have been treated for a bilateral retinoblastoma (Gonin-Laurent et al., 2006) . In this series of sarcomas, the rate of TP53 mutations was high (58%), and the mutation spectrum was characteristic of radiation exposure. However, the cellular pathways involved in the radiation-induced tumour formation were not precisely defined and the exact role of RB1 predisposing germline mutations was not known. The expression of p53 and pRb is precisely regulated and, in tumours, inactivation of the RB1 and TP53 pathways may involve the two suppressor genes, as well as one of the genes from their regulation network. The CDKN2A locus codes for two different proteins: p16
INK4a and p14 ARF . p16
INK4a interacts with cdk4 and induces G1 arrest by inhibiting pRb phosphorylation, whereas p14 ARF stabilizes p53 by inhibiting mdm2, and induces cell-cycle arrest in both G1 and G2/M. Activation of p16
INK4a and p14 ARF blocks the cell-cycle progression and induces the inhibition of cellular proliferation. Mutational and transcriptional inactivation of both genes has been reported in numerous kinds of carcinomas, as well as in bone and soft tissue sarcomas (Sharpless, 2005) . Overexpression of mdm2, achieved through MDM2 gene amplification or enhanced transcription, can lead to constitutive inhibition of p53 and cancer promotion without needing TP53 gene alteration (Lavin and Gueven, 2006) . The mdm2-related protein mdmx (or mdm4) is another key negative regulator of p53 function (Toledo and Wahl, 2006) . Mdmx binds to mdm2 and stimulates the ability of mdm2 to ubiquitinate and degrade p53 (Marine and Jochemsen, 2004) . Mdmx overexpression has been found in a number of primary tumours or tumour cell lines with wild-type p53 (Ramos et al., 2001; Danovi et al., 2004) , suggesting that mdmx may contribute to p53 inactivation during tumorigenesis. Recently, Laurie et al. (2006) showed that, in human retinoblastomas that retain wild-type TP53, p53 inactivation was owing to the over-expression of the p14 ARF -MDM2/MDMX pathway genes triggered by RB1 inactivation. To deepen our understanding of radiation tumorigenesis mechanisms, we have analysed the status of RB1, INK4a, ARF, MDM2 and MDMX in the series of radiation-induced sarcomas previously analysed for TP53 status.
Results and discussion
Thirty-six sarcomas developing in the field of irradiation of a primary cancer were collected at the Institut Curie (Table 1 and (Gonin-Laurent et al., 2006) . Twelve of these sarcomas developed in patients treated for bilateral retinoblastoma. Patients treated for retinoblastoma were irradiated in their early childhood (range 4-24 months, mean 10.6 months, median 11.5 months), whereas all other radiotherapies were performed during adulthood (range 19-74 years, mean 47.2 years, median 49 years). There was no statistical difference between the latency periods of sarcoma occurrence in retinoblastoma-predisposed patients (range 7-34 years, mean 17.7 years, median 16.5 years) and in patients without predisposition (range 7-36 years, mean 17 years, median 19 years) (Student's t-test, P>0.95). , presence of both forms; no protein, lack of protein due to the biallelic inactivation of the gene. Mutations were searched as described previously (Gonin-Laurent et al., 2006).
TP53 and RB1 pathways in radiation-induced sarcomas N Gonin-Laurent et al
We showed previously that 21 of the 36 sarcomas exhibited a somatic-inactivating mutation in one allele of TP53, together with a loss of the other allele. Such biallelic inactivation was observed in all sarcomas developing in predisposed patients, and only in nine of 24 (37%) of the tumours from patients without predisposition (Table 1 ; Gonin-Laurent et al., 2006) . The status of RB1 was also known for tumours one to seven: in all cases, only the germline-inactivated allele was present in the tumour cells, the other allele being lost (Lefe`vre et al., 2001) . We analysed the RB1 allelic status and the presence of mutations in cases 8-36 (Table 2 and Table S1 , Supplementary data). In genetically predisposed patients, one allele of the gene was lost in all cases. In cases 10-12, the germline mutation was found in the normal tissue and in the tumour. The synthesis of an active protein was prevented by the formation a stop codon downstream of the mutation (Table 2 ). In cases 8 and 9, no mutation was found in the sarcoma or in the normal tissue, despite complete DHPLC analysis and sequencing of all exons and of the promoter region. It is not known if there is actually no mutation or if the analytical methodology is inadequate. In non-predisposed patients, no mutation was found and loss of heterozygosity (LOH) was observed in 10 of the 14 cases for which normal DNA was available.
The expression and the phosphorylation status of pRb were analysed by Western blot in the 13 tumours for which protein extracts were available (Figure 1) . pRb was expressed in 11 of the 13 cases. In case 10, the absence of protein was in good agreement with the biallelic inactivation of the gene. In case 8, one allele of RB1 was lost and we could not determine if the remaining allele was mutated or not (see before). The absence of pRb in the protein extract suggests that the remaining allele was also inactivated. Cases 15, 23, 24 and 32 harboured a high expression level of pRb, Abbreviations: B, base position; bp, base pair; Co, codon; del, deletion; E, exon; I, intron; LOH, loss of heterozygosity; wt, wild-type Mutations in the RB1 gene were detected by DHPLC as described in Houdayer et al. (2004) . The analysis of reannealed PCR products was performed on a semiautomated 3500 high-throughput WAVE system (Transgenomic). Samples showing an abnormal DHPLC profile were sequenced. Mutations found in tumours were checked in normal tissue. in the genomic sequence of RB1 (Genebank accession number L11910). In case 11, the genomic deletion contained the last two bases of exon 15 (splicing site) and the first 30 bases of intron 15. Figure 1 Western blot analysis of pRb expression and phosphorylation. Control g-irradiated (7 Gy) MRC5 cell line: T1, immediately after irradiation (hyperphosphorylated pRB); T2, 24 h after irradiation (hypophosphorylated pRb). Exposure time 5 or 30 min. Electrophoresis was run with 100 mg of protein extract on a NuPAGE 3-8% Tris-acetate gel (Invitrogen, Cergy Pontoise, France), and Western blotting was performed using a mouse anti-pRb antibody (14001A, BD Pharmigen, Erembodegem, Belgium, 1/250, overnight at 41C) after transfer on polyvinylidene difluoride membrane (Immobilon-P, Millipore Corp., Saint Guentin en Yveline, France). The antibody detected underphosphorylated (110 kDa) and hyperphosphorylated (116 kDa) pRb (Chatterjee et al., 2004 (Sharpless, 2005) . In this series of sarcomas, we can conclude that, in addition to the cases with direct gene inactivation, the loss of Rb function occurred by hyperphosphorylation of the protein in three of 11 other tested tumours.
To investigate a possible upstream inactivation of the pathways, we studied genes involved in the regulation of p53 or pRb. Quantitative PCR was used to detect homozygous deletions at the CDKN2A locus in the 36 sarcomas. The four exons of the locus were analysed (Table 1 and Table S2 , Supplementary data). For six tumour DNAs (cases 3, 15, 17, 23, 24 and 27), the experimental curves merged with the control without DNA, and the calculated DDC t was higher than six for the four exons. These cases were scored as having a homozygous deletion of the whole locus. In the other cases, the DDC t ranged from À1 to 1.5, corresponding to the experimental error. Allelic status analysis was performed using microsatellites distributed in and around the locus (Table S3 Supplementary data). LOH was observed in seven of the 23 analysable cases (Table 1) . No somatic mutation was found in the INK4a and ARF genes by sequencing the four exons of the CDKN2A locus. The expression of the INK4a and ARF genes was analysed by real-time quantitative polymerase chain reaction (Table 3) . Only 13% of the sarcomas expressed the INK4a gene at a significant level (more than 0.1-fold the mRNA level found in the SaOS2 cell line); other tumours showed low or undetectable expression. For the ARF gene, the expression was very low or undetectable in the tumours (Table 3) . To test a possible mechanism of inactivation, the methylation status of seven CpG sites localized in the promoter region upstream from the first exon of INK4a was analysed by pyrosequencing (Table S4 Supplementary data). In each tumour, the levels of methylation were very similar at all analysed CpG. In 33 of the 34 analysed tumours, the percentage of methylation ranged between 0 and 5% at all CpG sites. This range of methylation is considered to be owing to experimental background (Shaw et al., 2006) . In case 30, the percentage of CpG methylation ranged between 11 and 14%, indicating that a small fraction of the tumour cells could have a methylated promoter, but that there was no global hypermethylation. In conclusion, INK4a and ARF genes were expressed at a very low level or not expressed in these radiation-induced sarcomas.
Homozygous deletion of the CDKN2A locus led to its inactivation in six of the 36 cases, whereas the hypermethylation of the promoter of INK4a did not cause the lack of gene expression in the other cases.
The amplification and expression status of MDM2 and MDMX were analysed (Table 3 ). Polysomy (3-4 copies of the gene by cell) or allele loss was found by quantitative PCR in some tumours, whereas an amplification was observed only in tumour 19 for MDM2 ( Â 50). MDM2 and MDMX were both overexpressed in three sarcomas (cases 2, 7 and 26), and MDM2 was overexpressed in two additional tumours (cases 19 and 32). Only in one tumour (case 19) was the overexpression associated with the amplification of the gene.
In some tumour types, a relationship has been found between pRb inactivation by hyperphosphorylation and the loss of p16
INK4a expression, but this association is not systematic (Sartor et al., 1999; Chatterjee et al., 2004) . In our series, various levels of phosphorylation of pRb were observed despite the lack of expression of INK4a. In particular, among the tumours with CDKN2A homozygous deletion where the complete absence of the p16
INK4a is certain, only case 17 showed pRb hyperphosphorylation (Table 1) . In four cases (15, 23, 24 and 27) , the two forms were observed. In the last case (case 3), the inactivation of both RB1 alleles prevents the protein expression. So, no link was found between the hyper-phosphorylation of pRb and the loss of INK4a. Similarly, no relationship was observed between ARF expression and the TP53 status (Table 1 ). In addition, in contrast with retinoblastomas (Laurie et al., 2006) , the inactivation of the RB1 gene in radiationinduced sarcomas developing in predisposed patients was not associated with the amplification/over-expression of the genes of the ARF/MDM2/MDMX pathway. Altogether, the data suggest that the INK4a and ARF pathways are not strongly involved in the regulation of TP53 and RB1 in the radiation-induced sarcomas.
Biallelic inactivation of TP53 was observed in 37% of the sarcomas from patients without predisposition, and in 100% (12 of 12) of the sarcomas from predisposed patients. RB1 was biallelically inactivated in 100% (11/11) of the sarcomas from predisposed patients (case 9 was not included as a definitive conclusion cannot be drawn regarding the RB1 status in this tumour). No RB1 somatic mutation was observed in sarcomas arising in non-predisposed patients. For both genes, the biallelic inactivation combined a point mutation for one allele (a somatic mutation for TP53 and the germline mutation for RB1) with the loss of a large part or all of the chromosome for the second allele (Table S1 and (Lefe`vre et al., 2001; Gonin-Laurent et al., 2006) . Among the analysed genes, only TP53 was an efficient target of the radiation-induced mutagenesis, with a panel of mutations characteristic of radiation exposure (Gonin-Laurent et al., 2006) . This indicates that the inactivation of one allele of TP53 is an early event selected during tumour formation. In contrast, the absence of radiation-induced somatic mutations in the RB1 gene suggests that, by themselves, such mutations would not strongly favour the initial tumour development and are not selected. However, even if the RB1 inactivation is not an early event in the tumorigenesis of these sarcomas, it is positively selected during the tumour progression. In the case of predisposition, the allelic losses do not occur randomly, and the normal allele is preferentially lost, whereas the germlineinactivated allele is retained. In contrast, in nonpredisposed patients, one allele is recurrently lost, but the other remains unaffected. Thus, the inactivation of RB1 is involved in the formation of radiation-induced sarcomas only in a genetic context of predisposition. However, the lack of a statistically significant difference between the latency periods for sarcomas developing in patients with or without predisposition shows that the time to sarcoma occurrence was not influenced by RB1 status. This suggests that the role of RB1 in the predisposition to radiation-induced sarcomas is not linked to its functions in cell proliferation. Indeed, recent data indicate that the gene has additional functions in the control of cell differentiation and survival (review in Goodrich, 2006) . In cells without active RB1 gene, the perturbation of these regulation pathways may influence tumour progression.
No somatic mutation was found in the coding sequence of the INK4a and ARF genes. This lack of inactivation by point mutation in radiation-induced sarcomas is in good agreement with data from the sporadic forms: in a total of 129 analysed sarcomas reported in the literature, only one mutation was Gene expression was measured by real-time fluorescent quantitative RT-PCR (RT-Q-PCR). One microgram of total RNA was reverse-transcribed with oligo(dT) by the SuperScript II system according to the manufacturer's protocol (Invitrogen). For each experiment, 1/100th of the reaction was amplified with specific primer pairs using the GeneAmp 7500 sequence detection system and SYBR Green PCR Kits (Applied Biosystems, Courtaboeuf, France). Data from duplicate samples were normalized to GAPDH expression. The mean threshold cycle numbers (C t ) were first determined for all samples. The DC t between tumour and control were calculated for each gene (DC tG ) and GAPDH (DC tGA ). DDC t corresponding to DC G -DC tGA were then calculated. The calculated 2 ÀDDCt is the fold change relative to that of SaOS2 osteosarcoma cell line used as control. The same approach was used to measure the amplification of MDM2 and MDMX. The DDC t between the DC tDMD for the MDM2 or MDMX gene and the DC tGA for the GAPDH gene were calculated. The amount 2
ÀDDCt is the ratio between the copy numbers of the MDM2 or MDMX and GAPDH genes. nd, not done because of homozygous deletion at the CNKN2A locus; na, not available.The sequences of primers used for these analyses are presented in supplementary data Table S5. TP53 and RB1 pathways in radiation-induced sarcomas N Gonin-Laurent et al observed (Patino-Garcia and Sierrasesumaga, 1997; Tsuchiya et al., 2000; Kawaguchi et al., 2003) . The INK4a gene was not or was very poorly expressed in a large fraction of the sarcomas (Table 3 ). In addition to the six homozygous deletions of the gene, this lack of expression could be linked to the inactivation by hypermethylation of the promoter: in a recent study of 65 sporadic sarcomas, INK4a methylated promoter was found in 9% of the cases (Kawaguchi et al., 2006) . However, in our series, the INK4a promoter was hypermethylated in none of the tumours, indicating that this epigenetic mechanism was not involved in the repression of the gene. It has been suggested that the inactivation of INK4a is preferentially selected in tumours with an active RB1 (Sharpless, 2005) . However, in our study, no relationship was found between the inactivation of INK4a and the allelic or the phosphorylation status of pRb (Tables 1 and 3 ). Thus, p16
INK4a
does not seem to be a significant regulator of the pRb pathway in these sarcomas. The activation of the ARF/MDM2/MDMX pathway was shown to be a mechanism of inactivation of p53 in tumours expressing the wild-type form of the protein (Ramos et al., 2001; Danovi et al., 2004; Laurie et al., 2006) . In our series of radiation-induced sarcomas, the genes of this pathway were rarely overexpressed (Tables 1 and 3) . ARF was not significantly expressed in tumours with biallelic inactivation of TP53 (cases 1-21), or in those expressing the wild-type allele (cases 22-36). MDM2 and MDMX were generally expressed at low levels, again unrelated to TP53 status. Only one amplification (2.8%) was observed for MDM2 (cases 19). This is significantly lower than the values of 20-30% generally found in sporadic sarcomas (Miller et al., 1996; Kawaguchi et al., 2002; Perucca-Lostanlen et al., 2004) , and strengthens the conclusion regarding the secondary role played by the ARF/MDM2/MDMX pathway in the radiation-induced sarcomas.
The biallelic inactivation of the RB1 gene was thought to be sufficient for the development of retinoblastoma in humans (Knudson, 2001) , as no mutation of TP53 is observed (Kato et al., 1996) . However, it has recently been shown that, in these tumours, the suppression of the p53 response is owing to the activation of the ARF/ MDM2/MDMX pathway after RB1 loss (Laurie et al., 2006) . In the radiation-induced sarcomas developing in people harbouring a germline inactivation of one allele of RB1, the RB1 and TP53 genes are also both inactivated, but the inactivation of TP53 takes place by genetic lesions and not by activation of the ARF/ MDM2/MDMX pathway. Thus, in this genetic context, the same tumorigenesis pathways are used in mesenchymal and retinal cells, but in radiation-induced sarcomas the inactivation of TP53 is a consequence of the irradiation and not of the RB1 loss. This conclusion strengthens the proposal that TP53 inactivation is an early triggering event in these sarcomas. Finally, it should be noted that in about 40% of the tumours of the series, neither the TP53 nor RB1 pathway was inactivated. So, unidentified pathways and other genes targeted by radiation-induced damage must be involved in the development of these radiation-induced sarcomas.
